Fig. 6

CKN is a novel LXRα agonist. Docking of CKN to mouse LXRα was simulated by SYBYL-X 2.0 (A). HEK293T cells were treated with different concentrations of CKN, and GW3965 (10 μM) was used as a positive control (B). The RAW264.7 cell proteins were mixed with compound CKN (30 μM), and the control group was treated with 0.5% DMSO. The proteins were heated at 45 to 69 °C under the same conditions using a heat block for 2 min. The supernatant was collected for western blotting (C). Diagram of the molecular mechanisms of CKN (D). Data are presented as mean ± SD (n = 3) and were analyzed by ANOVA with Dunnett’s post-hoc analysis